Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Christian Waldherr(University of California, Los Angeles), Johannes Czernin(University of California, Los Angeles), Arash Safaei, Daniel Silverman(University of California, Los Angeles), Benjamin S. Halpern(University of California, Santa Barbara), Nagichettiar Satyamurthy, Ingo K. Mellinghoff(Memorial Sloan Kettering Cancer Center), Nora Rozengurt, Michael E. Phelps(National Academy of Engineering), David Stout(Institute for Molecular Medicine), Jorge R. Barrio, Chris Tran, Wolfgang Weber(Nuklearmedizinische Klinik des Klinikums rechts der Isar), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center)
PubMed
January 1, 2005
Cited by 104
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Global imprint of climate change on marine life
|Nature Climate Change|2013|2.3k
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k